In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Absolut Vodka inks new partnership in biodegradable bottle pursuit
In Sweden, Absolut Vodka has inked a new partnership with start-up Blue Ocean Closures to increase the use of biodegradable materials in its packaging....
“Magic” mushrooms take centerstage at Glastonbury music festival
In the United Kingdom, acoustic panels made from hemp and mycelium were used in the ceiling of a dance music tent at the recent ...
Beverage company and designer create Dirt Shoe that disintegrates in minutes
In New York, beverage company Yerba Madre and design studio Basura have partnered to create shoes out of dirt, organic fibers, and acacia gum...